John Francis  Cogan net worth and biography

John Cogan Biography and Net Worth

Director of Gilead Sciences

John Cogan is the retired lead independent director of Gilead Sciences, a position he held for seven years. 

Cogan spent 15 years on Gilead’s board, beginning in 2005. He currently serves as the Leonard and Shirley Ely Senior Fellow at the Hoover Institution and as a professor for Stanford University’s public policy program. 

Cogan’s career began in 1975 when he served for five years as an associate economist at RAND Corporation. By 1979, he was appointed a national fellow at the Hoover Institution; by 1980, he became a senior research fellow; and by 1984, he was a senior fellow. Cogan has held a number of positions in the U.S. government, beginning in 1981 as assistant secretary for public policy in the U.S. Department of Labor under President Ronald Reagan. He continued with the administration until 1989, working as the associate director of the U.S. office of management and budget and as deputy director of the same office. His responsibilities included social security, disability, employment training, healthcare and welfare. 

Public service again played a role in Cogan’s career when he served on President George W. Bush’s Commission to Strengthen Social Security, among other initiatives. Cogan was also part of California’s Commission on the 21st Century Economy and the California Public Employee Post-Employment Benefits Commission. 

During his time at Stanford, Cogan has served on various faculty advisory boards for the Stanford-in-Washington campus and the Stanford Institute for Economic Policy Research. His own research focuses on U.S. fiscal and budget policy, healthcare and federal entitlement programs. Cogan has been widely published in professional journals across the political science and economic industries, and he has written three books. One of his books, The High Cost of Good Intentions, won the 2018 Hayek Prize. He is also the recipient of the Stanford-in-Government Distinguished Service Award. 

Cogan currently serves on the board of trustees for the Charles Schwab Family of Funds, where he is chairman of the board’s governance committee. Cogan holds an A.B. from the University of California at Los Angeles in economics, where he also earned his Ph.D. He completed his M.A. in economics from California State University at Long Beach.

What is John Francis Cogan's net worth?

The estimated net worth of John Francis Cogan is at least $5.28 million as of May 4th, 2020. Mr. Cogan owns 57,276 shares of Gilead Sciences stock worth more than $5,283,138 as of November 14th. This net worth evaluation does not reflect any other investments that Mr. Cogan may own. Learn More about John Francis Cogan's net worth.

How do I contact John Francis Cogan?

The corporate mailing address for Mr. Cogan and other Gilead Sciences executives is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. Gilead Sciences can also be reached via phone at (650) 574-3000 and via email at [email protected]. Learn More on John Francis Cogan's contact information.

Has John Francis Cogan been buying or selling shares of Gilead Sciences?

John Francis Cogan has not been actively trading shares of Gilead Sciences during the past quarter. Most recently, John Francis Cogan sold 2,416 shares of the business's stock in a transaction on Monday, May 4th. The shares were sold at an average price of $81.75, for a transaction totalling $197,508.00. Following the completion of the sale, the director now directly owns 57,276 shares of the company's stock, valued at $4,682,313. Learn More on John Francis Cogan's trading history.

Who are Gilead Sciences' active insiders?

Gilead Sciences' insider roster includes Gregg Alton (EVP), Paul Carter (EVP), John Cogan (Director), Andrew Dickinson (Exec. VP & CFO ), Andrew Dickinson (CFO), John Martin (Director), Johanna Mercier (Insider), James Meyers (EVP), John Milligan (Insider), Daniel O'Day (Chairman & CEO ), Merdad Parsey (Insider), Brett Pletcher (EVP), Javier Rodriguez (Director), Robin Washington (CFO), Richard Whitley (Director), and Diane Wilfong (CAO). Learn More on Gilead Sciences' active insiders.

Are insiders buying or selling shares of Gilead Sciences?

In the last year, insiders at the biopharmaceutical company sold shares 9 times. They sold a total of 81,679 shares worth more than $6,935,730.32. The most recent insider tranaction occured on November, 6th when insider Merdad Parsey sold 25,590 shares worth more than $2,341,485.00. Insiders at Gilead Sciences own 0.2% of the company. Learn More about insider trades at Gilead Sciences.

Information on this page was last updated on 11/6/2024.

John Francis Cogan Insider Trading History at Gilead Sciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/4/2020Sell2,416$81.75$197,508.0057,276View SEC Filing Icon  
4/27/2020Sell2,413$79.90$192,798.7057,273View SEC Filing Icon  
4/20/2020Sell2,413$83.00$200,279.0057,273View SEC Filing Icon  
4/13/2020Sell2,413$75.90$183,146.7057,273View SEC Filing Icon  
4/6/2020Sell2,413$79.52$191,881.7657,273View SEC Filing Icon  
3/30/2020Sell2,413$75.35$181,819.5557,273View SEC Filing Icon  
3/23/2020Sell2,413$75.27$181,626.5157,273View SEC Filing Icon  
3/16/2020Sell2,413$67.26$162,298.3857,273View SEC Filing Icon  
3/9/2020Sell2,413$77.97$188,141.6157,273View SEC Filing Icon  
5/1/2019Sell2,868$64.89$186,104.5257,728View SEC Filing Icon  
4/24/2019Sell2,700$62.61$169,047.0057,560View SEC Filing Icon  
4/17/2019Sell2,700$64.23$173,421.0057,560View SEC Filing Icon  
4/10/2019Sell2,700$67.23$181,521.0057,560View SEC Filing Icon  
4/3/2019Sell2,700$66.74$180,198.0057,560View SEC Filing Icon  
3/27/2019Sell2,700$64.14$173,178.0057,560View SEC Filing Icon  
3/20/2019Sell2,700$65.07$175,689.0057,560View SEC Filing Icon  
5/4/2018Sell5,836$65.09$379,865.2458,455View SEC Filing Icon  
4/27/2018Sell5,833$73.91$431,117.0358,452View SEC Filing Icon  
4/20/2018Sell5,833$73.74$430,125.4258,452View SEC Filing Icon  
4/13/2018Sell5,833$75.56$440,741.4858,452View SEC Filing Icon  
4/6/2018Sell5,833$74.47$434,383.5158,452View SEC Filing Icon  
3/23/2018Sell5,833$75.02$437,591.6658,452View SEC Filing Icon  
3/16/2018Sell5,833$80.09$467,164.9758,452View SEC Filing Icon  
3/12/2018Sell5,833$80.93$472,064.69View SEC Filing Icon  
5/9/2017Sell9,943$67.25$668,666.7547,562View SEC Filing Icon  
11/24/2015Sell15,000$105.95$1,589,250.0044,309View SEC Filing Icon  
10/27/2015Sell15,000$110.00$1,650,000.0044,309View SEC Filing Icon  
10/26/2015Sell15,000$110.00$1,650,000.0044,309View SEC Filing Icon  
9/15/2015Sell15,000$110.00$1,650,000.0044,309View SEC Filing Icon  
6/26/2015Sell27,000$120.13$3,243,510.00View SEC Filing Icon  
12/22/2014Sell26,000$95.03$2,470,780.00View SEC Filing Icon  
9/22/2014Sell5,000$106.60$533,000.00View SEC Filing Icon  
8/21/2014Sell5,000$101.09$505,450.00View SEC Filing Icon  
7/21/2014Sell5,000$89.67$448,350.00View SEC Filing Icon  
6/23/2014Sell5,000$81.82$409,100.00View SEC Filing Icon  
4/8/2014Sell5,000$70.55$352,750.0039,542View SEC Filing Icon  
3/14/2014Sell14,000$76.44$1,070,160.0039,542View SEC Filing Icon  
7/2/2013Sell17,000$51.66$878,220.00View SEC Filing Icon  
6/7/2013Sell110,000$52.15$5,736,500.00View SEC Filing Icon  
See Full Table

John Francis Cogan Buying and Selling Activity at Gilead Sciences

This chart shows John Francis Cogan's buying and selling at Gilead Sciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Gilead Sciences Company Overview

Gilead Sciences logo
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
Read More

Today's Range

Now: $92.24
Low: $91.29
High: $92.51

50 Day Range

MA: $86.22
Low: $78.72
High: $97.90

2 Week Range

Now: $92.24
Low: $62.07
High: $98.90

Volume

4,199,160 shs

Average Volume

7,064,631 shs

Market Capitalization

$114.84 billion

P/E Ratio

1,024.89

Dividend Yield

3.17%

Beta

0.17